Herantis Pharma extends HER-096 Phase 2 placebo-controlled treatment period to nine months
Bitget2026/11/05 06:59- Herantis Pharma highlighted newly published evidence supporting its HER-096 Phase 2 trial design, showing smartphone assessments detect Parkinson’s progression more sensitively.
- The trial will assess efficacy in approximately 100 recently diagnosed patients not receiving symptomatic medication, using smartphone-based motor assessments.
- Placebo-controlled treatment will increase from six to nine months, followed by six months of HER-096 treatment for all participants.
- The extended treatment period will not increase estimated study costs or overall funding requirements through the Phase 2 readout.
- Trial application submission is targeted for Q4 2026, with first dosing expected in H1 2027, subject to financing and regulatory approvals.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
